Hepatitis B immunization regimen and compositions

An immunogenic combination comprising:

• a) a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a polynucleotide encoding a hepatitis B virus core antigen (HBc);
• b) a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a polynucleotide encoding a hepatitis B virus core antigen (HBc), wherein the polynucleotides encoding HBs and HBc are separated by a polynucleotide encoding the 2A cleaving region of the foot and mouth disease virus (FMDV);
• and
• c) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B virus core antigen (HBc) comprising amino acids 1-145, 1-146, 1-147, 1-148, or 1-149 of a wild-type hepatitis B virus core antigen protein, and an adjuvant.

A kit comprising the following components:

• a) a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a polynucleotide encoding a hepatitis B virus core antigen (HBc);
• b) a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a polynucleotide a hepatitis B virus core antigen (HBc), wherein the polynucleotides encoding HBs and HBc are separated by a polynucleotide encoding the 2A cleaving region of the foot and mouth disease virus (FMDV);
• and
• c) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B virus core antigen (HBc) comprising amino acids 1-145, 1-146, 1-147, 1-148, or 1-149 of a wild-type hepatitis B core antigen protein, and an adjuvant,
• with instructions for administration of the components sequentially or concomitantly for the treatment of chronic hepatitis B (CHB).